For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
7
views
0
references
 Top references
cited by
235
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      0
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

      Author(s):
      Publication date:
      Journal: The New England journal of medicine
      Publisher: Massachusetts Medical Society

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis.

          Related collections

          Author and article information

          Journal
          PubMed ID:: 22375970
          DOI:: 10.1056/NEJMoa1110556

          Data availability:

          Comments

          Comment on this article

          scite_